vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and TREX CO INC (TREX). Click either name above to swap in a different company.
TREX CO INC is the larger business by last-quarter revenue ($343.4M vs $183.1M, roughly 1.9× Amphastar Pharmaceuticals, Inc.). TREX CO INC runs the higher net margin — 17.9% vs 13.3%, a 4.5% gap on every dollar of revenue. On growth, TREX CO INC posted the faster year-over-year revenue change (1.0% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-143.4M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -4.5%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Trex Company, Inc. is a manufacturer of wood-alternative composite decking, residential railing, and other outdoor items made from recycled materials. Its headquarters is in Winchester, Virginia.
AMPH vs TREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $343.4M |
| Net Profit | $24.4M | $61.4M |
| Gross Margin | 46.8% | 40.5% |
| Operating Margin | 19.4% | 24.3% |
| Net Margin | 13.3% | 17.9% |
| Revenue YoY | -1.8% | 1.0% |
| Net Profit YoY | -35.7% | 1.6% |
| EPS (diluted) | $0.51 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $343.4M | ||
| Q4 25 | $183.1M | $161.1M | ||
| Q3 25 | $191.8M | $285.3M | ||
| Q2 25 | $174.4M | $387.8M | ||
| Q1 25 | $170.5M | $340.0M | ||
| Q4 24 | $186.5M | $167.6M | ||
| Q3 24 | $191.2M | $233.7M | ||
| Q2 24 | $182.4M | $376.5M |
| Q1 26 | — | $61.4M | ||
| Q4 25 | $24.4M | $2.3M | ||
| Q3 25 | $17.4M | $51.8M | ||
| Q2 25 | $31.0M | $75.9M | ||
| Q1 25 | $25.3M | $60.4M | ||
| Q4 24 | $38.0M | $9.8M | ||
| Q3 24 | $40.4M | $40.6M | ||
| Q2 24 | $37.9M | $87.0M |
| Q1 26 | — | 40.5% | ||
| Q4 25 | 46.8% | 30.2% | ||
| Q3 25 | 51.4% | 40.5% | ||
| Q2 25 | 49.6% | 40.8% | ||
| Q1 25 | 50.0% | 40.5% | ||
| Q4 24 | 46.5% | 32.7% | ||
| Q3 24 | 53.3% | 39.9% | ||
| Q2 24 | 52.2% | 44.7% |
| Q1 26 | — | 24.3% | ||
| Q4 25 | 19.4% | 2.2% | ||
| Q3 25 | 13.2% | 24.7% | ||
| Q2 25 | 24.2% | 26.4% | ||
| Q1 25 | 21.9% | 24.0% | ||
| Q4 24 | 24.2% | 9.2% | ||
| Q3 24 | 29.8% | 23.2% | ||
| Q2 24 | 30.3% | 31.1% |
| Q1 26 | — | 17.9% | ||
| Q4 25 | 13.3% | 1.4% | ||
| Q3 25 | 9.0% | 18.1% | ||
| Q2 25 | 17.8% | 19.6% | ||
| Q1 25 | 14.8% | 17.8% | ||
| Q4 24 | 20.4% | 5.8% | ||
| Q3 24 | 21.1% | 17.4% | ||
| Q2 24 | 20.8% | 23.1% |
| Q1 26 | — | $0.58 | ||
| Q4 25 | $0.51 | $0.03 | ||
| Q3 25 | $0.37 | $0.48 | ||
| Q2 25 | $0.64 | $0.71 | ||
| Q1 25 | $0.51 | $0.56 | ||
| Q4 24 | $0.74 | $0.10 | ||
| Q3 24 | $0.78 | $0.37 | ||
| Q2 24 | $0.73 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $4.5M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $995.8M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.5M | ||
| Q4 25 | $282.8M | $3.8M | ||
| Q3 25 | $276.2M | $11.4M | ||
| Q2 25 | $231.8M | $5.5M | ||
| Q1 25 | $236.9M | $5.0M | ||
| Q4 24 | $221.6M | $1.3M | ||
| Q3 24 | $250.5M | $12.8M | ||
| Q2 24 | $217.8M | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $995.8M | ||
| Q4 25 | $788.8M | $1.0B | ||
| Q3 25 | $776.7M | $1.0B | ||
| Q2 25 | $757.5M | $989.3M | ||
| Q1 25 | $751.3M | $910.1M | ||
| Q4 24 | $732.3M | $850.1M | ||
| Q3 24 | $727.7M | $887.9M | ||
| Q2 24 | $713.3M | $894.9M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-118.4M |
| Free Cash FlowOCF − Capex | $24.6M | $-143.4M |
| FCF MarginFCF / Revenue | 13.4% | -41.8% |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | -1.93× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $224.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-118.4M | ||
| Q4 25 | $32.9M | $65.5M | ||
| Q3 25 | $52.6M | $196.9M | ||
| Q2 25 | $35.6M | $249.8M | ||
| Q1 25 | $35.1M | $-154.0M | ||
| Q4 24 | $29.0M | $-8.5M | ||
| Q3 24 | $60.0M | $132.8M | ||
| Q2 24 | $69.1M | $193.7M |
| Q1 26 | — | $-143.4M | ||
| Q4 25 | $24.6M | $22.1M | ||
| Q3 25 | $47.2M | $142.9M | ||
| Q2 25 | $25.0M | $203.0M | ||
| Q1 25 | $24.4M | $-233.5M | ||
| Q4 24 | $16.6M | $-89.3M | ||
| Q3 24 | $46.2M | $54.5M | ||
| Q2 24 | $63.1M | $158.2M |
| Q1 26 | — | -41.8% | ||
| Q4 25 | 13.4% | 13.7% | ||
| Q3 25 | 24.6% | 50.1% | ||
| Q2 25 | 14.3% | 52.3% | ||
| Q1 25 | 14.3% | -68.7% | ||
| Q4 24 | 8.9% | -53.3% | ||
| Q3 24 | 24.1% | 23.3% | ||
| Q2 24 | 34.6% | 42.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 26.9% | ||
| Q3 25 | 2.8% | 18.9% | ||
| Q2 25 | 6.1% | 12.1% | ||
| Q1 25 | 6.3% | 23.4% | ||
| Q4 24 | 6.7% | 48.2% | ||
| Q3 24 | 7.2% | 33.5% | ||
| Q2 24 | 3.3% | 9.4% |
| Q1 26 | — | -1.93× | ||
| Q4 25 | 1.35× | 28.45× | ||
| Q3 25 | 3.03× | 3.80× | ||
| Q2 25 | 1.15× | 3.29× | ||
| Q1 25 | 1.39× | -2.55× | ||
| Q4 24 | 0.76× | -0.87× | ||
| Q3 24 | 1.48× | 3.27× | ||
| Q2 24 | 1.82× | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
TREX
Segment breakdown not available.
